Now we’ve dispensed with the nonsense “gay gene” trope, let’s interrogate the way we talk about genetics and traits full stop
By Philip Ball,
Prospect
| 09. 04. 2019
Some people once felt that the reason to look for a “gay gene” was so that it could be eliminated. Under the headline “Abortion hope after ‘gay genes’,” in 1993 the Daily Mail wrote “Isolation of the genes [causing homosexuality] means it could soon be possible to predict whether a baby will be gay and give the mother the option of an abortion.”
Revisiting that reporting now it has been announced that there is no “gay gene” shows us how much has changed over less than three decades in public attitudes to homosexuality. Sadly, there has not been a comparable change in public attitudes to genes. Few would now take the abhorrent view that a genetic propensity to being gay would constitute good grounds for termination of a pregnancy, but probably many would have no problem believing that your genes could “make you gay” in the first place. This latest interrogation of genetic determinism illustrates how far we have still to go to shift the prevailing narrative about genes.
The new research, led by a team at the Broad...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...